Publications

Allen B, Vincent M, Lipworth L, Panko J, Suh M, Jiang X, Mumma MT, Proctor D. Lung cancer risk and exposure to hexavalent chromium: Results of extended mortality study of workers with low level exposures and quantitative risk assessment using pooled analysis of three cohorts. Poster presentation at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Thompson CM, Heintz MM, Rogers SI, Fitch SE, Rivera BN, Klaren WD, Vincent MJ, Wikoff DS, Haws LC. Evidence identification and appraisal supporting development of an updated toxicity value for HFPO-DA. Abstract 3654, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Heintz M, Klaren W, East A, Haws L, Thompson C. Delayed transcriptomic responses in PPARa knockout mouse hepatocytes compared to wild-type hepatocytes exposed to HFPO-DA or PPARa agonist GW7647: Support for a PPARa-dependent mode of action for HFPO-DA in mouse hepatocytes. Abstract 4100, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

DeVito, Bokkers B, van Duursen M, van Ede K, Feeley M,… Haws L,… Wikoff D, et al. The 2022 WHO reevaluation of human and mammalian toxic equivalency factors for polychlorinated dioxins, dibenzofurans and biphenyls. Abstract 3626, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Petrick J, Mihalchik A, Tiwary A, Kreidl L, Swartz C, Bhattarai N. Nonclinical safety evaluation of 1-monoacetin and 2-monoacetin as potential impurities in pharmaceutical excipients. Abstract 3107, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Franke K, Vincent M, Rogers S, Rivera B, Wikoff D. Assessment of non-occupational exposures to cleaning products and the incidence of asthma and respiratory disease. Abstract 3393, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; doi :10.1016/j.annonc.2023.10.262.

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734. ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125. ISPOR EU 2023.

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547. ISPOR EU 2023.

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658. ISPOR EU 2023.

Rish W, Marschke S, Racz L, Mauro J. Radiation exposures from the beneficial use of alumina production residue (red mud). Poster presented at Society of Environmental Toxicology and Chemistry North America 44^th Annual Meeting, Louisville, KY, November 2023.

Racz L, Mittal L, Perry CS, Blanchette A, Proctor D. Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling. Poster presented at Society of Environmental Toxicology and Chemistry North America 44^th Annual Meeting, Louisville, KY, November 2023.

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309. AMP 2023 Annual Meeting & Expo.

Kramer AJ. Introduction to inhalation exposure modeling. Technical presentation at AIHA Upper Midwest Local Section Professional Development Conference, Roseville, MN, November 2023.

Franklin M, Emden MR, Bauer E, Nguyen AT, Sacks N, Kawamatsu S, Kawano Y,  Mitrani-Gold FS, Joshi AV, Ju S, Preib MT. Prevalence of acute uncomplicated cystitis in Japan. Poster presentation, IDWeek, October 2023.

Franklin M, Emden MR, Kautz S, Nguyen AT, Sacks NC, Ju S, Mitrani-Gold FS, Joshi AV, Preib MT. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States. Poster presentation, IDWeek, October 2023.

Nelson CB, Jiang X, Suh M, Fryzek J. Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a greater benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020. Poster 1536169, IDWeek 2023, Boston, MA, October 2023.